<DOC>
	<DOCNO>NCT01163825</DOCNO>
	<brief_summary>Cholinergic neuron basal forebrain project widely cerebral cortex hippocampus . These neuron depend nerve growth factor ( NGF ) target area survival . Impaired NGF supply part Alzheimer 's disease ( AD ) pathology , degeneration neuron correlate cognitive decline patient . The objective encapsulate cell biodelivery ( ECB ) maintain normal level NGF support cholinergic function . NsGene 's NGF secrete ECB device ( NsG0202 ) combine potential benefit target gene therapy safety retrievable implantable device . The study open label , single centre , 12-month , dose-escalation phase Ib study patient mild moderate AD . The primary objective safety tolerability , secondary outcome measure include cognition , behaviour , neuropsychology , activity daily live ( ADL ) , positron emission tomography ( PET ) image electroencephalography ( EEG ) .</brief_summary>
	<brief_title>Encapsulated Cell Biodelivery Nerve Growth Factor AlzheimerÂ´s Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Age 5080 year 2 . All patient must fulfil NINDNDSARDRA criterion Alzheimer 's disease . 3 . The subject must score 1524 inclusive , minimental state examination ( MMSE ) . 4 . The subject must caregiver able committed assist subject comply trial protocol , willing provide information require assessment interview . 5 . Informed consent must obtain subject together close caregiver , accordance requirement ethical committee . 1 . A diagnosis Schizophrenia , Schizoaffective disorder paranoid disorder accord DSM IV without suspicion cognitive decline . 2 . Patients follow coexist medical condition : 3 . History seizure . 4 . Brain tumor include meningeoma . 5 . Clinically significant hepatic , renal , pulmonary , metabolic endocrine disturbance . 6 . Clinically significant back pain . 7 . Bleeding disorder . 8 . Patients , opinion investigator , otherwise unsuitable trial type .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>